Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-duodenal continuous gelled levodopa infusion versus optimized medical therapy for advanced severe Parkinson's disease
2010-020769-25Phase 2Active
- Sponsor
- CHU de Poitiers
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of levodopa in Parkinson's disease (PD) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: Change in quality of life at 6 months. Started Jul 2010; status: active.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2010-020769-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020769-25.